#Astellas Pharma

[radioshiga]

China indicia funcionário de farmacêutica japonesa por espionagem

Pequim, China, 22 de agosto de 2024 – Agência de Notícias Xinhua – Um executivo japonês da Astellas Pharma foi formalmente indiciado na China após aproximadamente 17 meses de detenção, elevando as tensões diplomáticas entre os dois países asiáticos. O homem, na faixa dos 50 anos, foi detido em Pequim em março de 2023 pelas autoridades de segurança chinesas sob suspeita de envolvimento em…

[mindblowingscience]

The ability to precisely control whether a gene is turned on or off is expected to lead to more efficient production of compounds that are made using animal cells, and make gene therapy, cell therapy and regenerative medicine safer.

For genes to be expressed, cells make many RNA copies of a section of DNA. These RNA copies, called transcripts, are then used to make the protein. Scientists can take advantage of this process by introducing additional genes (either as DNA or RNA) into cells, which can then be used to make new proteins for a wide variety of applications. For example, in gene therapy, disorders caused by faulty proteins can be treated by introducing genes into body cells that code for working versions of that protein and in regenerative medicine, the expression of inserted genes could reprogram cells. Proteins with drug applications, like hormones and antibodies, can also be easily produced and collected by inserting genes into cultured cells.

However, after introducing DNA or RNA into cells, scientists need to be able to precisely control the production of the protein, so that it is made at the right time and in the right amount. This maximizes productivity and could help avoid unnecessary side effects in patients.

Continue Reading

[mariacallous]

Once upon a time, a very long time ago, about two years ago, companies—like the beloved children’s character Winnie the Pooh—lived, if not all by themselves, then at least far from geopolitics.

How rapidly the world has changed since then. Last year, a staggering 93 percent of multinationals reported losses linked to political instability, up from 35 percent in 2020, a new survey from WTW and Oxford Analytica found. Companies should brace themselves for even more turbulence this year. And next year. And the year after that. Businesses, which have for decades operated in a world where they could float above any squabbling among countries, are discovering that charmed era has ended.

Weeks after Russia invaded Ukraine, BP decided to let go of its 19.75-percent stake in the Russian oil and gas giant Rosneft and two joint ventures in Russia—which meant it had to write down more than $20 billion in the first quarter of 2022. The German DIY chain Obi Baumarkt sold its Russian stores to local staff for 10 euros. The Italian bank UniCredit has lost $1.3 billion, ExxonMobil has lost more than $3 billion, and H&M has lost nearly $200 million. Indeed, every company leaving the country (and hundreds have made announcements to that effect) is incurring substantial losses—if they manage to leave.

Companies wishing to depart need the approval of Russian authorities, and as of March this year, they also have to make a “mandatory donation” to the Russian government. Meanwhile, companies operating in China, or exporting to the country, know that they risk becoming a target if their home governments say or do something that displeases Beijing; this has happened to companies as diverse as Ericsson and Taiwanese pineapple farms. And when President Tsai Ing-wen of Taiwan met U.S. Speaker of the House Kevin McCarthy in California earlier this month, Beijing responded by dispatching an “inspection flotilla” to the Taiwan Strait, where its threat of inspections was certain to wreak havoc on shipping companies and their customers in one of the world’s busiest waterways. This time, the flotilla didn’t carry out any inspections, but global shipping companies and manufacturers rightly concluded there will be more such outings.

Such events have delivered a brutal awakening to companies, which until just a couple of years ago persisted in believing that they could keep operating in a largely peaceful sphere. The 2023 political risk survey conducted by Oxford Analytica for the insurance broker WTW, published on April 18, delivers sobering figures. Last year, 68 percent of companies bought political risk insurance, which provides cover for war, civil wars, coups, government expropriations, and similar misfortunes, up from 25 percent in 2019.

Even compared to last year, the fear of geopolitics has skyrocketed. In the 2022 survey, 16 percent of the executives interviewed predicted deglobalization would significantly strengthen; in this year’s report, 48 percent do (and another 38 percent believe it will simply strengthen). Last year, 12 percent of the executives predicted decoupling from China would significantly increase; now 42 percent do. Beijing has been all too happy to oblige. The Financial Times reported that between mid-February and mid-April this year, China imposed sanctions on the U.S. defense contractors Lockheed Martin and Raytheon; launched an investigation into U.S. chipmaker Micron; and harassed the U.S. due diligence firm Mintz, Japan’s Astellas Pharma group, and the Big Four consultancy Deloitte.

A sizable majority of executives have lost faith in globalization. “It’s a sea change in companies’ attitudes about geopolitical risk,” Sam Wilkin, WTW’s director of political analysis, told me. “There has been a huge change in perception, mostly as a result of the conflict in Ukraine and, for U.S. companies, the confrontation with China. Companies have started taking wars and conflicts seriously.” (Full disclosure: I serve as an occasional advisor to another division of WTW.)

Companies are taking wars and conflicts seriously because they’re being affected by both—including conflicts of the less visible kind. Twenty percent of the companies surveyed have sustained political risk-related losses in Russia or Ukraine, and 48 percent have done so in the BRICS countries—Brazil, Russia, India, China, and South Africa. “Political uncertainty manifested in the war in Ukraine and the growing uncertainty around China and a potential war in the Pacific over Taiwan: Link this to continued uncertainty over rogue states like North Korea and Iran, and it’s no surprise that political uncertainty and the impact it has on international business is growing,” said Simon Bergman, the CEO of M&C Saatchi World Services. “The West’s inability to accurately predict large state actors’ behavior has been manifest over the past 12 months, and this will continue into 2024 and beyond.”

Political risk insurance cover was created years ago with the backing of several Western governments to allow companies to operate in riskier countries. Today, though, simply operating in the globalized economy is so risky that nearly 7 in 10 companies are buying this insurance. “Companies’ ability to do business in Russia and China will continue to deteriorate,” Bergman said. “When, and it’s when, China acts on Taiwan, the international reaction will significantly impact global businesses, and many of them depend on China for commercial products. The impact will be significant if not crisis-bringing.”

Nearly two-thirds of the executives surveyed by Oxford Analytica are concerned about state-backed cyber aggression, and nearly 60 percent worry about sanctions targeting individuals and companies. More than 50 percent worry about state-backed manipulation of financial markets, and more than 40 percent are concerned about state-backed intellectual-property theft.

So dire is the situation for the corporates surveyed that Russia and China now account for the largest political risk losses, followed by India, Brazil, and (thanks to Brexit) the United Kingdom. In 2020, companies sustained their largest political risk losses in Iran, Venezuela, Zimbabwe, Angola, and Libya—a much more predictable bunch of countries, and much more manageable losses because most companies had smaller operations there than in Russia or China. China taking the place of the Angolas and Libyas of the world, measured in business risk, is a dramatic turn of events.

“The risk the business community is most worried about is the West vs. China, because Western countries are showing that they’re willing to treat China as a systemic competitor,” Wilkin said. “And now it’s possible to imagine a major economy leaving the globalized economy. In 2020, we still had some of the usual suspects ranking as the world’s riskiest. Back then, you could operate in politically risky countries because you had diversified operations including many countries with no or little political risk. Now political risk has shifted major world economies that used to be major investment destinations. Companies are worrying about going out of business as a result of political risk.”

It has come to this: Businesses are worried about going bust not as a result of misunderstanding the market or making foolish investments—but as a result of geopolitics. Western companies in particular are extremely vulnerable now that globalization’s ultimate prize, China, is not just battling the United States over global power but also battling its own private sector, lest it become uncomfortably powerful. So severe was Beijing’s recent crackdown of China’s most successful tech giants that the companies’ shares plummeted when President Xi Jinping was reelected to a third term last fall.

“If the rate of change on the outside exceeds the rate of change on the inside, the end is near,” GE’s legendary CEO Jack Welch said. It’s not looking good for the companies that have done precisely what they were supposed to do and spent the past three decades integrating themselves into the globalized economy.

[latestmarketresearchnews]

DNA Synthesis Market 2030: Brief Analysis of Top Countries Data, Growth and Drivers

The global DNA synthesis market was valued at USD 3.13 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 15.30% from 2024 to 2030. This growth can largely be attributed to the increasing demand for DNA synthesis driven by its applications in several fields, including molecular biology, genetic engineering, and clinical diagnostics and therapeutics. Additionally, the rising need for research in drug discovery and personalized medicine is expected to further boost market expansion during the forecast period.

The market is also seeing moderate merger and acquisition activity, driven by factors such as the desire to enhance competitive positioning within the industry and the need for consolidation in a rapidly growing market. Companies are increasingly entering into collaborations to support advancements in research and development (R&D) in diagnostics and therapeutics. For example, in April 2023, Twist Bioscience, a leader in the DNA synthesis market, announced a collaboration with Astellas Pharma to assist in antibody discovery for immunotherapies. These strategic alliances are expected to strengthen the market's growth trajectory as they enhance innovation in gene-related research.

Gather more insights about the market drivers, restrains and growth of the DNA Synthesis Market

Regional Insights:

North America DNA Synthesis Market Trends

North America held the largest market share, accounting for 39.76% of the global revenue in 2023. The region’s growth is driven by heightened public awareness about genetic disorders, along with robust medical facilities and substantial investments in research and development. The prevalence of chronic illnesses, such as cancer, diabetes, and cardiovascular diseases, further amplifies the demand for DNA synthesis as a tool for understanding and treating these conditions. Additionally, North American market players are heavily investing in gene synthesis and gene therapy research, creating a fertile environment for growth. The presence of leading DNA synthesis companies in the region, along with continuous advancements in gene editing technologies, further supports regional expansion.

U.S.

The U.S. DNA synthesis market has been experiencing significant growth, largely driven by the increasing demand for synthetic DNA and RNA sequences for various applications. These include molecular research, diagnostics, and therapeutics. The market's competitive landscape is diverse, consisting of both established players and emerging companies that are eager to secure a share of this expanding market. The U.S. market is particularly influenced by advancements in personalized medicine and genetic therapies, which heavily rely on DNA synthesis for drug development, disease prevention, and treatment personalization.

Asia Pacific DNA Synthesis Market Trends

The DNA synthesis market in the Asia Pacific region is anticipated to grow at the fastest rate, with a CAGR of 17.50% from 2024 to 2030. This growth is attributed to the increasing demand for synthetic DNA in research, diagnostics, and therapeutics, along with the rising prevalence of genetic diseases and the growing need for personalized medicine.

China

China is expected to experience the highest growth rate in the DNA synthesis market, with a projected CAGR of 21.41%. Factors contributing to this growth include the rising number of contract research organizations (CROs) and the outsourcing of drug discovery and development activities by pharmaceutical and biotech companies. Additionally, China’s focus on expanding and upgrading its gene synthesis facilities is further accelerating market growth. For example, in May 2023, GenScript expanded its oligonucleotide manufacturing facility in Jiangsu, China, to enhance its production capacity.

Japan

Japan is also expected to witness significant growth due to its aging population and emphasis on personalized medicine. As a leader in scientific research, especially in biotechnology and biopharmaceuticals, Japan has a strong focus on genetic studies and gene expression profiling, which are crucial to the DNA synthesis market. These factors are expected to further drive the demand for DNA synthesis in the region.

India

The DNA synthesis market in India is anticipated to grow rapidly due to the country’s high birth rate and the significant prevalence of genetic disorders, exacerbated by factors like consanguineous marriages and founder mutations. Government initiatives, such as the "Make in India" program and biotechnology R&D grants, are empowering domestic players and attracting foreign investments. Notably, the Department of Biotechnology (DBT) launched the UMMID initiative in 2019 to address inherited genetic diseases in newborns, further stimulating the DNA synthesis market.

Europe DNA Synthesis Market Trends

Europe represents another key region in the DNA synthesis market. This is largely due to strong government support, continuous advancements in research infrastructure, and an increasing prevalence of chronic diseases like cancer, cardiovascular conditions, and genetic disorders. The growing adoption of gene therapy is also contributing to the market's growth.

UK

The DNA synthesis market in the UK is poised for growth, driven by ongoing research and innovation in genetics and molecular studies. Government initiatives and strong healthcare infrastructure provide a conducive environment for biomedical research. For instance, in November 2023, the UK's approval of the CRISPR-based gene-editing therapy Casgevy marked a significant milestone, positioning the UK DNA synthesis market for further growth.

France

France faces a significant burden from cancer, which remains a leading cause of death in the country. The demand for DNA synthesis in France is driven by its growing role in cancer diagnostics and personalized medicine, particularly through gene expression profiling and liquid biopsies. Furthermore, cardiovascular diseases, such as atherosclerosis and heart failure, are contributing to the growing interest in oligonucleotides and genetic profiles for both diagnostic and therapeutic purposes, pushing the demand for DNA synthesis technologies.

Germany

Germany’s DNA synthesis market is expected to grow due to the country’s strong R&D focus in diagnostics and therapeutics. Germany is actively promoting biotechnology and healthcare infrastructure through initiatives like “Industrie 4.0” and providing grants for R&D. These efforts not only boost the domestic market but also attract foreign investment, further driving the DNA synthesis market in Germany.

Browse through Grand View Research's Category Biotechnology Industry Research Reports.

The global exosomes market size was estimated at USD 177.4 million in 2024 and is anticipated to grow at a CAGR of 28.73% from 2025 to 2030.

The global cell culture media storage containers market size was estimated at USD 2.11 billion in 2024 and is projected to witness a CAGR of 12.55% from 2025 to 2030.

Key DNA Synthesis Companies:

Thermo Fisher Scientific, Inc

Twist Bioscience

BIONEER CORPORATION

Eton Bioscience, Inc.

LGC Biosearch Technologies

IBA Lifesciences GmbH

Eurofins Scientific

Integrated DNA Technologies, Inc.

Quintara Biosciences

GenScript

Order a free sample PDF of the DNA Synthesis Market Intelligence Study, published by Grand View Research.

[researchreportinsight]

DNA Synthesis Market Research Report 2030 By Players, Regions, Types & Applications

The global DNA synthesis market was valued at USD 3.13 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 15.30% from 2024 to 2030. This growth can largely be attributed to the increasing demand for DNA synthesis driven by its applications in several fields, including molecular biology, genetic engineering, and clinical diagnostics and therapeutics. Additionally, the rising need for research in drug discovery and personalized medicine is expected to further boost market expansion during the forecast period.

The market is also seeing moderate merger and acquisition activity, driven by factors such as the desire to enhance competitive positioning within the industry and the need for consolidation in a rapidly growing market. Companies are increasingly entering into collaborations to support advancements in research and development (R&D) in diagnostics and therapeutics. For example, in April 2023, Twist Bioscience, a leader in the DNA synthesis market, announced a collaboration with Astellas Pharma to assist in antibody discovery for immunotherapies. These strategic alliances are expected to strengthen the market's growth trajectory as they enhance innovation in gene-related research.

Gather more insights about the market drivers, restrains and growth of the DNA Synthesis Market

Regional Insights:

North America DNA Synthesis Market Trends

North America held the largest market share, accounting for 39.76% of the global revenue in 2023. The region’s growth is driven by heightened public awareness about genetic disorders, along with robust medical facilities and substantial investments in research and development. The prevalence of chronic illnesses, such as cancer, diabetes, and cardiovascular diseases, further amplifies the demand for DNA synthesis as a tool for understanding and treating these conditions. Additionally, North American market players are heavily investing in gene synthesis and gene therapy research, creating a fertile environment for growth. The presence of leading DNA synthesis companies in the region, along with continuous advancements in gene editing technologies, further supports regional expansion.

U.S.

The U.S. DNA synthesis market has been experiencing significant growth, largely driven by the increasing demand for synthetic DNA and RNA sequences for various applications. These include molecular research, diagnostics, and therapeutics. The market's competitive landscape is diverse, consisting of both established players and emerging companies that are eager to secure a share of this expanding market. The U.S. market is particularly influenced by advancements in personalized medicine and genetic therapies, which heavily rely on DNA synthesis for drug development, disease prevention, and treatment personalization.

Asia Pacific DNA Synthesis Market Trends

The DNA synthesis market in the Asia Pacific region is anticipated to grow at the fastest rate, with a CAGR of 17.50% from 2024 to 2030. This growth is attributed to the increasing demand for synthetic DNA in research, diagnostics, and therapeutics, along with the rising prevalence of genetic diseases and the growing need for personalized medicine.

China

China is expected to experience the highest growth rate in the DNA synthesis market, with a projected CAGR of 21.41%. Factors contributing to this growth include the rising number of contract research organizations (CROs) and the outsourcing of drug discovery and development activities by pharmaceutical and biotech companies. Additionally, China’s focus on expanding and upgrading its gene synthesis facilities is further accelerating market growth. For example, in May 2023, GenScript expanded its oligonucleotide manufacturing facility in Jiangsu, China, to enhance its production capacity.

Japan

Japan is also expected to witness significant growth due to its aging population and emphasis on personalized medicine. As a leader in scientific research, especially in biotechnology and biopharmaceuticals, Japan has a strong focus on genetic studies and gene expression profiling, which are crucial to the DNA synthesis market. These factors are expected to further drive the demand for DNA synthesis in the region.

India

The DNA synthesis market in India is anticipated to grow rapidly due to the country’s high birth rate and the significant prevalence of genetic disorders, exacerbated by factors like consanguineous marriages and founder mutations. Government initiatives, such as the "Make in India" program and biotechnology R&D grants, are empowering domestic players and attracting foreign investments. Notably, the Department of Biotechnology (DBT) launched the UMMID initiative in 2019 to address inherited genetic diseases in newborns, further stimulating the DNA synthesis market.

Europe DNA Synthesis Market Trends

Europe represents another key region in the DNA synthesis market. This is largely due to strong government support, continuous advancements in research infrastructure, and an increasing prevalence of chronic diseases like cancer, cardiovascular conditions, and genetic disorders. The growing adoption of gene therapy is also contributing to the market's growth.

UK

The DNA synthesis market in the UK is poised for growth, driven by ongoing research and innovation in genetics and molecular studies. Government initiatives and strong healthcare infrastructure provide a conducive environment for biomedical research. For instance, in November 2023, the UK's approval of the CRISPR-based gene-editing therapy Casgevy marked a significant milestone, positioning the UK DNA synthesis market for further growth.

France

France faces a significant burden from cancer, which remains a leading cause of death in the country. The demand for DNA synthesis in France is driven by its growing role in cancer diagnostics and personalized medicine, particularly through gene expression profiling and liquid biopsies. Furthermore, cardiovascular diseases, such as atherosclerosis and heart failure, are contributing to the growing interest in oligonucleotides and genetic profiles for both diagnostic and therapeutic purposes, pushing the demand for DNA synthesis technologies.

Germany

Germany’s DNA synthesis market is expected to grow due to the country’s strong R&D focus in diagnostics and therapeutics. Germany is actively promoting biotechnology and healthcare infrastructure through initiatives like “Industrie 4.0” and providing grants for R&D. These efforts not only boost the domestic market but also attract foreign investment, further driving the DNA synthesis market in Germany.

Browse through Grand View Research's Category Biotechnology Industry Research Reports.

The global exosomes market size was estimated at USD 177.4 million in 2024 and is anticipated to grow at a CAGR of 28.73% from 2025 to 2030.

The global cell culture media storage containers market size was estimated at USD 2.11 billion in 2024 and is projected to witness a CAGR of 12.55% from 2025 to 2030.

Key DNA Synthesis Companies:

Thermo Fisher Scientific, Inc

Twist Bioscience

BIONEER CORPORATION

Eton Bioscience, Inc.

LGC Biosearch Technologies

IBA Lifesciences GmbH

Eurofins Scientific

Integrated DNA Technologies, Inc.

Quintara Biosciences

GenScript

Order a free sample PDF of the DNA Synthesis Market Intelligence Study, published by Grand View Research.

[pharmaceuticals2]

Global Prostate Cancer Therapeutics Market: Trends, Opportunities, and Challenges

With prostate cancer among the most common cancers in men, and within its various forms and stages, much research and development have been conducted in this space. The global prostate cancer therapeutics market has grown immensely in the past few years, given the rising prevalence of the disease, more sensitive diagnostic techniques, and new treatments.

This analysis is meant to discuss the main driving factors, challenges, and future trends in the dynamic landscape.

The prostate cancer therapeutics market is expected to grow from US$ 14,767.73 million in 2022 to US$ 28,425.27 million by 2030; it is estimated to witness a CAGR of 8.5% during 2022-2030.

Market Dynamics

Key Drivers:-Poor lifestyle and diet coupled with older age, have enhanced an increased incidence of prostate cancers all over the world. New and advanced diagnostic technologies will make it possible to conduct early detection and diagnosis through highly sensitive imaging techniques and markers so that intervention takes place timely.

Advances in therapy: Phase I pipelines of targeted therapies, immunotherapies, and radiopharmaceuticals offer promise as potential treatmentoptions for patients diagnosed with advanced diseases. Financial support from governments and relatively relaxed regulations speed up the drug development process and inmarket commercialization process.

Challenges

Side Effects: All the current treatments used, including chemotherapy and hormonal treatment, cause highly discomforting side effects in the patients, so they interrupt their lifestyle. At some point, it may begin to show signs of drug resistance, and therefore, new approaches may be needed in treatment.

Treatment Expense: Advanced treatments, particularly new biologics, are too expensive and thus not available to many patients.

Market Segmentation-

By Therapy Type

Hormonal Therapy

Chemotherapy

Targeted Therapy

Immunotherapy

By End User

Hospitals

Specialty Clinics

By Region

North America

Europe

Asia-Pacific

South and Central America

Middle East and Africa

Key Players

Astella Pharma Inc

Johnson Johnson Services Inc

Eli Lilly and Company

Bayer AG

Sanofi

Merck KGaA

AstraZeneca

Novartis AG

AbbVie

Future Prospect

The prostate cancer therapeutics market has bright prospects with several trends in its favor:

Personalized Medicine: Customized treatment plans based on the specific characteristics of the patient could be made possible through developments in genomics and proteomics.

Combination Therapies: A combination of modalities can potentially give a greater efficient effect while reducing the side effects.

Liquid Biopsies: Circulating tumor DNA in blood samples will allow detection, monitoring of disease progression and response to treatment.

Artificial Intelligence:AI-assisted analytics in drug discovery, designing clinical trials, patient management

Conclusion

The prostate cancer therapeutics market continues to grow through the increasing prevalence of the disease, advancement in technology, and encouragement of new therapies in the pipeline. Despite these growth drivers, side effects, drug resistance, and the costliness of treatments still exist in the industry. Upon overcoming these challenges, the search for opportunities will help secure the improvement in outcomes for patients and alter the current scenarios of prostate cancer treatment.

Frequently Asked Questions-

Largest regional market for Prostate Cancer Therapeutics?

Ans: North America is the largest regional market for Prostate Cancer Therapeutics.

Which are the leading companies that hold market share in the Prostate Cancer Therapeutics market?

Ans: - Astella Pharma Inc, Johnson & Johnson Services Inc, Eli Lilly and Company, Bayer AG, Sanofi, Merck KGaA, AstraZeneca, Novartis AG, AbbVie, and Bristol Myers Squibb are the top companies to hold the market share.

What would be the growth rate of the market to be projected during the forecast period 2022 to 2030?

Ans: - In the forecasting years, the market of Prostate Cancer Therapeutics is likely to see an 8.5% CAGR from 2022 to 2030.

Prostate Cancer Therapeutics Market Size?

Ans: - The market size of Prostate Cancer Therapeutics globally was valued at US$ 14,767.73 million in 2022 and is expected to reach US$ 28,425.27 million by 2030.

Segments for Prostate Cancer Therapeutics Market?

Ans: The Prostate Cancer Therapeutics market can be segmented by Therapy Type, End User, and region.

About Us-

The Insight Partners is among the leading market research and consulting firms in the world. We take pride in delivering exclusive reports along with sophisticated strategic and tactical insights into the industry. Reports are generated through a combination of primary and secondary research, solely aimed at giving our clientele a knowledge-based insight into the market and domain. This is done to assist clients in making wiser business decisions. A holistic perspective in every study undertaken forms an integral part of our research methodology and makes the report unique and reliable.

[marketprofessional]

"Overactive Bladder Treatment Market Insights: New Solutions for Better Patient Care"

Overactive Bladder Treatment Market Overview📊 :

The Overactive Bladder Treatment Market Report is a treasured source of insightful data for business strategists. It provides an in-depth assessment of numerous features of industries like market overview, present progress valuations, historical and future studies, current trends, SWOT valuations, and clients operating in several regions. The study provides valuable information to magnify the understanding, scope, and segments of this report. The report covers a comprehensive analysis of Overactive Bladder Treatment Market segmentation and regional and country breakdowns. This research will offer a clear and exact idea about the whole industry to the readers to make beneficial decisions.

According to Straits Research, the global Overactive Bladder Treatment Market size was valued at USD 4.1 Billion in 2022. It is projected to reach from USD XX Billion in 2023 to USD 5.73 Billion by 2031, growing at a CAGR of 3.8% during the forecast period (2023–2031).

This study pinpoints noteworthy trends influencing the trajectory of the Gesture Recognition market's expansion. Within this recently issued report, crucial dynamics encompassing drivers, limitations, and prospects are underscored. These aspects hold relevance for well-established market entities as well as emerging stakeholders engaged in the realms of production and supply.

Request a Sample Report @ https://straitsresearch.com/report/overactive-bladder-treatment-market/request-sample

Who are the 🏆leading players in Overactive Bladder Treatment Market? 

AbbVie Inc.

Allergan PLC.

Apotex Inc.

Astellas Pharma Inc.

Aurobindo Pharma Limited

Cogentix Medical Inc.

Endo International PLC

Hisamitsu Pharmaceutical Co. Inc.

Intas Pharmaceuticals Ltd.

Johnson & Johnson

Macleods Pharmaceuticals Ltd.

Medtronic PLC

Mylan N.V.

Pfizer Inc.

Sanofi

Teva Pharmaceutical Industries Limited.

Moreover, the competitive analysis of the Overactive Bladder Treatment Market brings insight into the product usability profiles of the leading players. Additionally, the analysis highlights features & pricing, and informant reviews of the key products in the market.

Which segments are covered in Overactive Bladder Treatment Market?

By Pharmacotherapy

Anticholinergics

Botox

Intravesical Instillation

Mirabegron

Neurostimulation

By Disease Type

Idiopathic Overactive Bladder

Neurogenic Overactive Bladder

The market is largely fragmented and the vast majority of the players functioning in the global Overactive Bladder Treatment Market are taking steps to raise their market footprint, by concentrating on product diversification and development, therefore making them seize a larger share of the market. The study highlights current market trends and provides a forecast. We also have highlighted future trends in the Overactive Bladder Treatment Market that will impact the demand during the forecast period. Overall, this report is an important resource for businesses seeking to stay ahead of the competition in the Overactive Bladder Treatment Market industry. With its complete analysis of recent developments and the latest emerging trends, it offers valuable insights into the market that can be used to grow effective growth strategies and enhance market positioning.

Access Detailed Segmentation @ https://straitsresearch.com/overactive-bladder-treatment-market/segmentation

Regional Analysis

Largest Market: The Overactive Bladder Treatment Market is dominated by North America, which holds the largest share due to factors such as advanced infrastructure, high consumer awareness, and significant investment in related industries. The region's well-established specific sectors further bolster its leading position in the market.

Fastest Growing Market: The fastest-growing market for Overactive Bladder Treatment Market is Asia Pacific. This growth is driven by a combination of rising disposable incomes, increasing adoption of specific products or services, and supportive government initiatives. Additionally, the expanding related industries in this region contribute to its rapid market expansion.

Our Report Offers:

– Market share assessments for the regional and country-level segments.

– Strategic recommendations for the new entrants.

– Competitive landscaping mapping the key common trends.

– Company profiling with detailed strategies, financials, and recent developments.

– Supply chain trends mapping the latest technological advancements.

Buy Now full Overactive Bladder Treatment Market report @ https://straitsresearch.com/buy-now/overactive-bladder-treatment-market/

An international Overactive Bladder Treatment Market research report delves into the competitive landscape of global markets, scrutinizing companies and manufacturers. The report's competitive analysis spotlights the strategic actions undertaken by key players across diverse industries. These actions encompass a spectrum of activities including new product introductions, expansions, agreements, joint ventures, partnerships, and recent acquisitions. This comprehensive market report sheds light on a myriad of facets within marketing research, spanning crucial industry trends, market size, estimated market share, sales volume, emerging patterns, product consumption, customer inclinations, historical data, forward-looking forecasts, and meticulous analysis of key players.

Global Overactive Bladder Treatment Market Research Report Forecast 2031

Chapter 1:- Overactive Bladder Treatment Market Overview

Chapter 2:- Economic Impact on Industry

Chapter 3:- Production, Business Opportunities with Potential Analysis

Chapter 4:- Rising Trends and New Technologies with Key Players

Chapter 5:- Overactive Bladder Treatment Market Manufacturing Cost Analysis

Chapter 6:- Technology Progress, Development Process and Downstream Buyers

Chapter 7:- Marketing Strategy Analysis, Distributors/Traders

Chapter 8:- Market Share by Key Countries in These Regions

Chapter 9:- Show the Market by Type and Application, With Sales Market Share and Growth Rate

Chapter 10:- Appendix and Data Source

Click to View the Full Report TOC: https://straitsresearch.com/report/overactive-bladder-treatment-market/toc

Key Questions Answered by Our Overactive Bladder Treatment Market Report

What are the key drivers of growth in the Overactive Bladder Treatment Market, and how do they vary across regions and segments?

How are advancements in technology and innovation affecting the Overactive Bladder Treatment Market, and what new opportunities and challenges are emerging as a result?

Which market players are currently leading the pack in terms of market share and product innovation, and what strategies are they employing to maintain their positions?

What regulatory and policy changes are on the horizon that could affect the Overactive Bladder Treatment Market, and how are market players adapting to these changes?

What are the emerging trends and market disruptors that are likely to shape the Overactive Bladder Treatment Market in the years to come, and what can businesses do to stay ahead of the curve?

How are consumer preferences and behaviors evolving with regard to Overactive Bladder Treatment Market, and what implications do these trends have for market players?

Buy Now full Overactive Bladder Treatment Market report @ https://straitsresearch.com/buy-now/overactive-bladder-treatment-market/

Thanks for reading this article; you can also get separate chapter-wise sections or region-wise report versions like North America, Europe, or Asia.

About Us:

Contact Us:

Email: sales@straitsresearch.com

Website: https://straitsresearch.com/

[harshnews]

Functional Bowel Disorder Agents Market Size, Share, Demand, Future Growth, Challenges and Competitive Analysis

"Functional Bowel Disorder Agents Market – Industry Trends and Forecast to 2029

Global Functional Bowel Disorder Agents Market, By Drug Class (Anticholinergics, Chloride Channel Activators, Guanylate Cyclase-C Agonists, NHE3 Inhibitors, Peripheral Opioid Receptor Antagonists, Peripheral Opioid Receptor Mixed Agonists/Antagonists, Serotoninergic Neuroenteric Modulators), Application (Irritable Bowel Syndrome, Chronic Bloating, Diarrhea, Constipation, Others), Dosage (Injection, Tablet, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Access Full 350 Pages PDF Report @

**Segments**

- By Drug Type: Laxatives, Antidiarrheal Agents, Antispasmodics, Others - By Disease Type: Irritable Bowel Syndrome (IBS), Functional Constipation, Functional Diarrhea, Others - By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

The market for functional bowel disorder agents is segmented by drug type, disease type, and distribution channel. In terms of drug type, the market is divided into laxatives, antidiarrheal agents, antispasmodics, and others. Laxatives are commonly used to treat constipation, antidiarrheal agents for diarrhea, and antispasmodics for abdominal pain and cramping associated with bowel disorders. The disease type segment includes irritable bowel syndrome (IBS), functional constipation, functional diarrhea, and others. IBS is a common disorder affecting the large intestine, leading to symptoms like cramping, abdominal pain, bloating, gas, diarrhea, and constipation. Functional constipation and diarrhea are conditions where bowel movements are not smooth and regular. Distribution channels for these agents include hospital pharmacies, retail pharmacies, and online pharmacies, providing accessibility to a wide range of consumers.

**Market Players**

- Allergan - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - GlaxoSmithKline plc - AstraZeneca - Bayer AG - Sebela Pharmaceuticals Inc. - Takeda Pharmaceuticals U.S.A., Inc. - Sucampo Pharmaceuticals (U.S.) - Ironwood Pharmaceuticals, Inc.

Key market players in the functional bowel disorder agents market include Allergan, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., GlaxoSmithKline plc, AstraZeneca, Bayer AG, Sebela Pharmaceuticals Inc., Takeda Pharmaceuticals U.S.A., Inc., Sucampo Pharmaceuticals (U.S.), and Ironwood Pharmaceuticals, Inc.The market for functional bowel disorder agents is highly competitive, with key players striving to gain a significant market share through product innovation, strategic partnerships, mergers, acquisitions, and geographical expansion. Allergan is a prominent player with a diverse portfolio of gastrointestinal products, including treatments for irritable bowel syndrome and constipation. Takeda Pharmaceutical Company Limited focuses on research and development to introduce novel therapies for functional bowel disorders. Astellas Pharma Inc. has a strong presence in the market, offering a range of antispasmodic agents for managing symptoms associated with bowel disorders.

GlaxoSmithKline plc and AstraZeneca are global pharmaceutical giants that have made significant investments in developing and commercializing medications for gastrointestinal conditions. Bayer AG is known for its expertise in healthcare and offers a wide range of products for gastrointestinal disorders. Sebela Pharmaceuticals Inc. specializes in gastrointestinal therapies and has a dedicated focus on providing effective solutions for functional bowel disorders. Takeda Pharmaceuticals U.S.A., Inc. is a subsidiary of Takeda Pharmaceutical Company Limited and plays a vital role in marketing and distributing gastrointestinal products in the U.S. market.

Sucampo Pharmaceuticals (U.S.) is known for its research in gastrointestinal diseases and has brought forth innovative treatment options for functional bowel disorders. Ironwood Pharmaceuticals, Inc. is a key player that has developed multiple medications for various gastrointestinal conditions, contributing to the overall growth of the market. These market players compete on the basis of product quality, efficacy, safety, pricing, and distribution channels to cater to the diverse needs of patients suffering from functional bowel disorders.

The functional bowel disorder agents market is driven by factors such as the increasing prevalence of gastrointestinal diseases, changing dietary habits, sedentary lifestyles, and the rising awareness among consumers about treatment options. Market players are focusing on expanding their product portfolios, conducting clinical trials, and collaborating with healthcare providers to enhance patient outcomes. Moreover, the growing geriatric population, who are more prone to gastrointestinal issues, is also driving the demand**Global Functional Bowel Disorder Agents Market, By Drug Class** - Anticholinergics - Chloride Channel Activators - Guanylate Cyclase-C Agonists - NHE3 Inhibitors - Peripheral Opioid Receptor Antagonists - Peripheral Opioid Receptor Mixed Agonists/Antagonists - Serotoninergic Neuroenteric Modulators

The global functional bowel disorder agents market is witnessing significant growth driven by various factors. The market segmentation by drug class includes a wide range of medications such as anticholinergics, chloride channel activators, guanylate cyclase-C agonists, NHE3 inhibitors, peripheral opioid receptor antagonists, peripheral opioid receptor mixed agonists/antagonists, and serotoninergic neuroenteric modulators. This diverse range of drug classes allows healthcare providers to address different symptoms and conditions associated with functional bowel disorders effectively. The application segment encompasses irritable bowel syndrome, chronic bloating, diarrhea, constipation, and others, reflecting the broad spectrum of conditions that these agents can target. The dosage forms include injections, tablets, and others, providing flexibility in treatment options for patients. Moreover, the route of administration includes oral, intravenous, and others, offering various options for healthcare providers to administer medications based on patient needs.

In terms of end-users, hospitals, specialty clinics, homecare settings, and others play a crucial role in ensuring access to these medications for patients suffering from functional bowel

Functional Bowel Disorder Agents Key Benefits over Global Competitors:

The report provides a qualitative and quantitative analysis of the Functional Bowel Disorder Agents Market trends, forecasts, and market size to determine new opportunities.

Porter’s Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make strategic business decisions and determine the level of competition in the industry.

Top impacting factors & major investment pockets are highlighted in the research.

The major countries in each region are analyzed and their revenue contribution is mentioned.

The market player positioning segment provides an understanding of the current position of the market players active in the Personal Care Ingredients

Table of Contents: Functional Bowel Disorder Agents Market

1 Introduction

2 Global Functional Bowel Disorder Agents Market Segmentation

3 Executive Summary

4 Premium Insight

5 Market Overview

6 Functional Bowel Disorder Agents Market, by Product Type

7 Functional Bowel Disorder Agents Market, by Modality

8 Functional Bowel Disorder Agents Market, by Type

9 Functional Bowel Disorder Agents Market, by Mode

10 Functional Bowel Disorder Agents Market, by End User

12 Functional Bowel Disorder Agents Market, by Geography

12 Functional Bowel Disorder Agents Market, Company Landscape

13 Swot Analysis

14 Company Profiles

Critical Insights Related to the Keyword Included in the Report:

Exclusive graphics and Illustrative Porter’s Five Forces analysis of some of the leading companies in this market

Value chain analysis of prominent players in the market

Current trends influencing the dynamics of this market across various geographies

Recent mergers, acquisitions, collaborations, and partnerships

Revenue growth of this industry over the forecast period

Marketing strategy study and growth trends

Growth-driven factor analysis

Emerging recess segments and region-wise market

An empirical evaluation of the curve of this market

Ancient, Present, and Probable scope of the market from both prospect value and volume

Browse Trending Reports:

Asia Pacific Mainframe Market

Asia Pacific Menstrual Cramps Treatment Market

Europe Commercial Cleaning Equipment Market

Europe Mainframe Market

Europe Quantum Computing Market

Europe Tomatoes Market

Europe Utility Locator Market

India Blood Gas Analyzer Market

Middle East And Africa Commercial Cleaning Equipment Market

Middle East And Africa Neurosurgery Market

Middle East And Africa Sports Medicine Market

Middle East And Africa Vaccines Market

Nigeria Cassava Starch Market

Nigeria Starch Processing Market

North America Menstrual Cramps Treatment Market

North America Neurosurgery Market

West Africa Baby Food Market

Antenna Market

Baby Apparel Market

Cassava Starch Market

Castor Oil Market

Cenospheres Market

Coconut Water Market

Collagen Casings Market

Facility Management Market

Functional Confectionery Market

Hemp Seed Market

Infrared Imaging Market

Instant Noodles Market

Laundry Detergents Market

Menstrual Cramps Treatment Market

Micro And Nano Plc Market

Motorcycle Market

Neurosurgery Market

Nickel Alloy Market

Over The Counter Probiotic Supplements Market

Polycystic Kidney Disease Adpkd Market

Private Label Food And Beverage Market

Recreational Cannabis Market

Tofu And Tempeh Market

Tomatoes Market

Vaccines Market

Varnish Makers Market

Wireless Medical Device Connectivity Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[market-insider]

Food Allergy Diagnostics And Therapeutics Market Insights: Detailed Overview of Market Size, Share, Projected Growth

The global food allergy diagnostics and therapeutics market size is expected to reach USD 13.28 billion by 2030, registering a CAGR of 8.0% during the forecast period, according to a new report by Grand View Research, Inc. The market is expected to grow in the coming years owing to increasing incidence of food allergies coupled with rising demand for products for management of these conditions.

Food Allergy Diagnostics And Therapeutics Market Report Highlights

Therapeutics segment dominated the market in 2023 due to growing demand for antihistamines and epinephrine auto-injector

Diagnostic segment includes instruments, consumables, and services, wherein consumables expected to grow at the fastest CAGR during the forecast period

The most common tests used to diagnose food allergies are skin prick tests and blood tests

Peanut allergen source segment is anticipated to register lucrative growth over the forecast period, owing to novel product launches coupled with rising incidence of peanut allergies worldwide.

Hospitals & clinics dominated the food allergy diagnostics & therapeutics market in 2023 owing to increase in number of hospitalizations due to severe allergic conditions

For More Details or Sample Copy please visit link @: Food Allergy Diagnostics And Therapeutics Market Report

Medical was the largest application for PEG, accounting for more than 40% of market share in 2022. Superior blending, hygroscopicity, and non-toxic properties of PEG have resulted in high demand for the chemical in numerous pharmaceutical products such as tablets and ointments. Increasing pharmaceutical expenditure, particularly in emerging economies of India, China, and Brazil, is expected to boost PEG market over the forecast period. Growing demand for paints & coatings coupled with the increasing use of PEG as a solvent due to its low VOC emissions is anticipated to fuel market growth over the next six years.

However, administering epinephrine using an auto-injector during the early stage of anaphylaxis might help avoid any serious complications. Treatment for food allergy costs around USD 25 billion annually in the U.S. Development of cost-effective in vitro diagnostic tests for detection of allergy is expected to fuel the demand for diagnostic products.

List of major companies in the Food Allergy Diagnostics And Therapeutics Market

Astellas Pharma, Inc.

Aimmune Therapeutics

Meridian Medical Technologies

ALK-Abelló Ltd

Medeca Pharma AB

bioMeriux SA

Omega Diagnostics Group PLC

HYCOR Biomedical

HOB Biotech Group Corp Ltd.

Cambridge Allergy Ltd

Medeca Pharma AB

For Customized reports or Special Pricing please visit @: Food Allergy Diagnostics And Therapeutics Market Analysis Report

We have segmented the global artificial food allergy diagnostics and therapeutics market based on product, allergen source, end-use, and region.

[conversationpoint]

Vernal Keratoconjunctivitis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Santen SAS, Novartis, Laboratoires Thea, Allakos Inc., Santen SASl, Astellas Pharma Inc

http://dlvr.it/TDr7z8

[thesunshinereporter]

Vernal Keratoconjunctivitis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Santen SAS, Novartis, Laboratoires Thea, Allakos Inc., Santen SASl, Astellas Pharma Inc

http://dlvr.it/TDr6TK

[columbianewsupdates]

Castrate-resistant Prostate Cancer Market to Show Remarkable Growth Trends from 2023 to 2032, Asserts DelveInsight | Pfizer, Astellas Pharma, Bristol-Myers Squibb, Laekna Therapeutics, Novartis

http://dlvr.it/TDbcp8

[newsheadlinesnow]

Chronic Constipation Market Growth Anticipated: Chronic Constipation Set for Robust Expansion upto 2032, Companies Includes Kissei Pharmaceutical Co., Wecare Probiotics Co., Astellas Pharma

http://dlvr.it/TDBXWH

[hopetribune]

Chronic Constipation Market Growth Anticipated: Chronic Constipation Set for Robust Expansion upto 2032, Companies Includes Kissei Pharmaceutical Co., Wecare Probiotics Co., Astellas Pharma

http://dlvr.it/TDBXTB

[universalnewspoint]

Chronic Constipation Market Growth Anticipated: Chronic Constipation Set for Robust Expansion upto 2032, Companies Includes Kissei Pharmaceutical Co., Wecare Probiotics Co., Astellas Pharma

http://dlvr.it/TDBVgM

[thealphareporter]

Chronic Constipation Market Growth Anticipated: Chronic Constipation Set for Robust Expansion upto 2032, Companies Includes Kissei Pharmaceutical Co., Wecare Probiotics Co., Astellas Pharma

http://dlvr.it/TDBTGy